Education
About Us
Working with TipRanks
Follow Us
Grifols SA (GRFS)
NASDAQ:GRFS
Top Page
Grifols SA
(NASDAQ:GRFS)
Rating:71Outperform
Price Target:
$12.00
▲(18.46% Upside)
Grifols SA (GRFS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.32B
Dividend Yield1.44%
Average Volume (3M)988.42K
Price to Earnings (P/E)20.2
Beta (1Y)0.95
Revenue Growth10.05%
EPS Growth98.22%
CountryUS
Employees23,833
SectorHealthcare
Sector Strength51
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)0.20
Shares Outstanding261,425,100
10 Day Avg. Volume535,262
30 Day Avg. Volume988,418
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap2.26
Enterprise Value/Revenue3.39
Enterprise Value/Gross Profit8.57
Enterprise Value/Ebitda16.15
Forecast
1Y Price Target
$10.30Price Target Upside1.68% Upside
Rating ConsensusHold
Number of Analyst Covering1
Grifols SA Business Overview & Revenue Model
Company DescriptionGrifols SA (GRFS) is a global healthcare company based in Spain that specializes in the production of plasma-derived medicines, with a focus on treating rare and chronic diseases. The company operates in three main segments: Bioscience, Diagnostic, and Hospital. Grifols is renowned for its innovative therapies, including immunoglobulins, albumin, and clotting factors, which are primarily used to treat patients with immune deficiencies, blood disorders, and other conditions.
How the Company Makes MoneyGrifols generates revenue primarily through the sale of its plasma-derived products, which are a significant portion of its revenue. The company operates a robust network of human plasma collection centers, which allows it to secure a steady supply of plasma for its manufacturing processes. Key revenue streams include sales from its Bioscience division, which provides therapies for patients with immune deficiencies and other chronic conditions. Additionally, Grifols earns revenue from its Diagnostic and Hospital segments, which offer a range of products and services for hospitals and laboratories. The company has established significant partnerships with healthcare institutions and organizations, enhancing its market reach and facilitating the distribution of its products. Factors contributing to Grifols' earnings include the increasing demand for blood products globally, advancements in biotechnology, and the company's commitment to research and development, which drives innovation and the introduction of new therapies.
Grifols SA Earnings Call Summary
Earnings Call Date:Jul 29, 2025
(Q1-2025)
| % Change Since: |
Next Earnings Date:Nov 06, 2025
Earnings Call Sentiment Positive
The earnings call presented strong revenue growth, improvements in adjusted EBITDA, and significant free cash flow improvement, highlighting the company's operational resilience and strategic execution. However, challenges such as negative free cash flow due to a one-time payment, phasing impacts in specific segments, and the financial impact of the Inflation Reduction Act were noted. Despite these challenges, the positive aspects of growth and efficiency improvements outweigh the negatives.Q1-2025 Updates
Positive Updates
Strong Revenue Growth
Revenue reached EUR1.786 billion, a 7.4% increase on a constant currency basis. On a like-for-like basis, revenue increased by 10%.
Adjusted EBITDA Improvement
Adjusted EBITDA for the quarter reached EUR400 million, an improvement of 14.2% at constant currency. Like-for-like, it grew by close to 22%.
Impressive Free Cash Flow Improvement
Free cash flow for the quarter improved by over EUR200 million year-on-year, despite being negative EUR44 million due to a EUR79 million payment to ImmunoTek.
Immunoglobulin Segment Growth
The immunoglobulin franchise achieved 17.5% growth in revenue at constant currency, led by both IV and subcutaneous IG.
Operational Efficiency Gains
Continued improvements in cost per liter and yield, along with a focus on operational leverage improvement.
Negative Updates
Negative Free Cash Flow
Free cash flow for the quarter was negative EUR44 million, primarily due to a EUR79 million payment to ImmunoTek.
Albumin and Rabies Segment Phasing Impact
Phasing in albumin and rabies impacted revenue, with albumin sales declining by 8.9% on a like-for-like basis due to a license renewal process in China.
Impact of Inflation Reduction Act
The Inflation Reduction Act resulted in a EUR28 million impact in Q1. The total estimated impact for 2025 remains at EUR125 million.
Company Guidance
In the first quarter of 2025, Grifols reported a robust financial performance, achieving a revenue of EUR1.786 billion, reflecting a 7.4% increase on a constant currency basis, and a 10% rise on a like-for-like basis. Adjusted EBITDA reached EUR400 million, marking a 14.2% improvement, and nearly 22% on a like-for-like basis. Despite a negative free cash flow of EUR44 million due to a payment to ImmunoTek, the company noted a year-on-year improvement of over EUR200 million. Grifols attributed this success to strong growth in their immunoglobulin franchise, with IV and subcutaneous IG growing impressively, particularly subcutaneous IG, which surged by 91% at constant currency. The company anticipates ongoing revenue growth, supported by improved performances in rabies, albumin, and alpha-1 franchises, alongside initiatives to lower costs and enhance operational efficiencies. Grifols remains committed to further deleveraging its balance sheet and achieving sustained revenue, profitability, and free cash flow growth throughout the year.Grifols SA Financial Statement Overview
Summary
Grifols SA has shown robust revenue growth and improved operating margins. However, the low net profit margin and high leverage present financial risks. Strong cash flow generation is positive but needs enhancement for better financial stability.Income Statement
Grifols SA demonstrates strong revenue growth with a 9.41% increase from 2023 to 2024. The gross profit margin improved to 38.74%, indicating efficient cost management. However, the net profit margin remains relatively low at 2.18%, suggesting potential cost or operational inefficiencies. The EBIT margin increased to 16.53%, reflecting better operating performance.72
Positive
Balance Sheet
The debt-to-equity ratio of 1.71 indicates a high level of leverage, which could pose risks if not managed properly. Return on equity is modest at 2.67%, suggesting room for improvement in profitability. The equity ratio of 27.49% highlights a stable asset base supported by equity, though there is reliance on debt.65
Positive
Cash Flow
Grifols SA shows a significant improvement in free cash flow, turning positive in 2024. The operating cash flow to net income ratio of 5.75 reflects strong cash generation capacity relative to net profits. However, the free cash flow to net income ratio of 3.38 indicates that cash flow improvements are still needed to enhance financial flexibility.68
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.55B | 7.21B | 6.59B | 6.06B | 4.93B | 5.34B |
| Gross Profit | 2.20B | 2.79B | 2.32B | 2.23B | 1.96B | 2.26B |
| EBITDA | 1.17B | 1.48B | 1.18B | 1.16B | 922.47M | 1.37B |
| Net Income | 180.38M | 156.92M | 59.31M | 208.28M | 265.33M | 618.55M |
Balance Sheet | ||||||
| Total Assets | 20.98B | 21.41B | 21.44B | 21.53B | 19.23B | 15.27B |
| Cash, Cash Equivalents and Short-Term Investments | 1.01B | 1.00B | 544.50M | 591.24M | 2.68B | 590.51M |
| Total Debt | 10.05B | 10.09B | 10.12B | 9.75B | 9.32B | 6.91B |
| Total Liabilities | 12.68B | 12.80B | 13.47B | 13.08B | 11.09B | 8.55B |
| Stockholders Equity | 5.64B | 5.88B | 5.83B | 6.13B | 6.10B | 5.11B |
Cash Flow | ||||||
| Free Cash Flow | 673.55M | 530.80M | -87.14M | -386.43M | 281.89M | 747.78M |
| Operating Cash Flow | 949.70M | 902.17M | 208.28M | -10.87M | 596.98M | 1.11B |
| Investing Cash Flow | -572.05M | 886.67M | -397.64M | -1.98B | -29.39M | -858.12M |
| Financing Cash Flow | -1.72B | -1.36B | 186.04M | -173.49M | 1.47B | -354.40M |
Grifols SA Technical Analysis
Positive
10.13
Price Trends
9.89
Positive
8.86
Positive
8.16
Positive
Market Momentum
-0.05
Positive
53.04
Neutral
48.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRFS, the sentiment is Positive. The current price of 10.13 is below the 20-day moving average (MA) of 10.17, above the 50-day MA of 9.89, and above the 200-day MA of 8.16, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 53.04 is Neutral, neither overbought nor oversold. The STOCH value of 48.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GRFS.
Grifols SA Risk Analysis
Grifols SA disclosed 53 risk factors in its most recent earnings report. Grifols SA reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Grifols SA Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $79.59B | 18.12 | 23.04% | 4.07% | 3.46% | -13.29% | |
72 Outperform | $112.36B | 12.41 | 8.39% | 4.76% | -9.32% | 120.62% | |
71 Outperform | $8.32B | 20.19 | 5.41% | 1.44% | 10.05% | 98.22% | |
68 Neutral | $95.03B | 19.17 | 29.31% | 5.22% | 2.57% | ― | |
68 Neutral | $139.93B | 22.48 | 33.26% | 2.71% | 3.69% | 501.26% | |
67 Neutral | $150.80B | 22.92 | 99.14% | 3.31% | 13.10% | 110.67% | |
51 Neutral | $7.92B | -0.43 | -41.69% | 2.21% | 22.29% | -1.85% |
* Healthcare Sector Average
Performance Comparison
GRFS
Grifols SA
10.13
1.67
19.74%
AMGN
Amgen
283.64
-31.73
-10.06%
BMY
Bristol-Myers Squibb
47.14
0.82
1.77%
GILD
Gilead Sciences
115.05
38.35
50.00%
GSK
GlaxoSmithKline
40.50
-1.55
-3.69%
SNY
Sanofi
46.50
-10.20
-17.99%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.